Business Wire

Wasabi Technologies Unveils Wasabi Cloud Sync Manager, Giving Companies the Power to Escape Vendor Lock In Without Egress Fees or Downtime

Share

Wasabi Technologies, the hot cloud storage company, today introduced Wasabi Cloud Sync Manager, the industry's most affordable and highest performing cloud migration tool that allows businesses globally to move their data out of expensive hyperscale cloud environments like AWS S3 to Wasabi without egress fees or downtime. It also delivers seamless replication and synchronization of data between different Wasabi regions to reduce latency, meet compliance requirements, and foster best practices for data backup and recovery. Customers benefit from the flexibility of shifting data between clouds at any time, the ability to protect copies of data in different regions while increasing their cloud data performance and response time, and reducing overall storage costs.

Skyrocketing cloud prices and the current economic climate are leading many businesses to tighten their budgets and look for more affordable cloud storage solutions. However, exorbitant costs associated with cloud to cloud migration, like egress and data retrieval fees, and technical infrastructure challenges to migrate data back on premise and then to a new cloud, force many to stay locked into their current vendor.

Wasabi Cloud Sync Manager bypasses the high costs and technical hurdles associated with cloud to cloud migration. It uses private network connections to migrate data from AWS, Azure, GCP, and other S3 compliant storage directly to Wasabi. This reduces egress costs from those providers, avoids internet latency and bottlenecks, and provides fast and predictable performance that lets users rapidly move massive datasets. Data is transferred with no downtime, enabling customers to continue putting data into their original cloud quickly, and without stopping the data transfer. Meanwhile, the bucket replication feature allows customers to copy objects from a storage bucket in a specific Wasabi region to a different bucket in another Wasabi storage region.This is ideal for adding an extra layer of data protection, meeting compliance and sovereignty requirements, or minimizing latency.

Wasabi hot cloud storage is significantly less expensive and markedly faster than AWS S3 and similar providers, meaning it can be universally applied to any storage use case such as active archiving, backup, disaster recovery, storage for a custom application (active data), and more. At 1/5th the cost of hyperscalers, with no fees for egress or API requests and no vendor lock-in, businesses are able to securely and affordably store all of their data and access it the moment they need to without complex pricing tiers. Wasabi Cloud Sync Manager helps users take advantage of lower cost storage as quickly as possible and start saving money right away.

“Wasabi’s singular focus is to deliver the best cloud storage in the world, and Cloud Sync Manager marks the next step in our mission,” said David Boland, vice president of cloud strategy at Wasabi Technologies. “Companies in the past may have wanted to leave their cloud provider, but couldn't afford to. Now, Wasabi Cloud Sync Manager allows customers to switch to the more affordable and higher performing Wasabi hot cloud storage for just pennies per GB, depending on the data source and geographical region, and start saving money immediately.”

For more information on Wasabi Cloud Sync Manager, visit https://wasabi.com/cloud-sync-manager/.

About Wasabi Technologies
Wasabi provides simple, predictable and affordable hot cloud storage for businesses all over the world. It enables organizations to store and instantly access an unlimited amount of data at 1/5th the price of the competition with no complex tiers or unpredictable egress fees. Trusted by tens of thousands of customers worldwide, Wasabi has been recognized as one of technology’s fastest-growing and most visionary companies. Created by Carbonite co-founders and cloud storage pioneers David Friend and Jeff Flowers, Wasabi is a privately held company based in Boston. Wasabi is a Proud Partner of the Boston Red Sox, and the Official Cloud Storage Partner of Liverpool Football Club and the Boston Bruins.

Follow and connect with Wasabi on Twitter, Facebook, Instagram, and The Bucket.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

wasabi@inkhouse.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR Positive, HER2 Low or Negative Metastatic Breast Cancer9.12.2022 00:00:00 CET | Press release

Initial results from the TROPION-PanTumor01 phase 1 trial of datopotamab deruxtecan (Dato-DXd) showed encouraging and durable efficacy in patients with heavily pretreated hormone receptor (HR) positive, HER2 low (immunohistochemistry [IHC] 1+ or IHC 2+/in-situ hybridization [ISH]-) or HER2 negative (IHC 0) unresectable or metastatic breast cancer. Safety data were consistent with previous trials of datopotamab deruxtecan. Results were presented today as a Spotlight Poster Discussion (Abstract #PD13-08) at the 2022 San Antonio Breast Cancer Symposium (#SABCS22). Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN). Approximately 70% of breast cancer tumors are considered HR positive and HER2 low or negative.1 For patients with HR positive, HER2 low or negative metastatic breast cancer that progress on or are not suitable candidates for endocrine the

TreviPay Acquires Apruve8.12.2022 23:45:00 CET | Press release

TreviPay, a leader in global B2B payments and invoicing solutions, today announced the signing of a definitive agreement to acquire payment platform Apruve. Apruve offers a robust suite of payment solutions for global enterprises that will complement and expand on TreviPay’s existing order-to-cash technology offerings, merchant invoicing solutions, and the geographical reach of TreviPay’s existing B2B networks. TreviPay has experienced unprecedented demand from global enterprise buyers and sellers resulting in 30% organic growth in 2022, and this acquisition furthers TreviPay's plans to expand its order-to-cash technology offerings and B2B payment network. This acquisition builds on TreviPay’s recent purchase of Baton Financial Services. “TreviPay provides payment and invoicing solutions for a number of leading manufacturers and OEMs; the acquisition of Apruve will accelerate our advancement in the technology manufacturing vertical and expand our geographic reach into key Asian markets

Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy8.12.2022 22:05:00 CET | Press release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the CONTACT-01 study did not meet its primary endpoint of overall survival (OS) at the final analysis. CONTACT-01 is a phase III clinical trial evaluating Cabometyx® (cabozantinib) in combination with atezolizumab (Tecentriq®) versus docetaxel in patients with unmutated metastatic non-small cell lung cancer (NSCLC) who experienced disease progression on or after treatment with an immune checkpoint inhibitor and platinum-containing chemotherapy. Howard Mayer, M.D., Executive Vice President, Head of Research and Development at Ipsen, said: “The results from the CONTACT-01 clinical trial have shown the challenge of treating NSCLC patients after prior lines of treatment have failed. While the findings of the study have not met the primary endpoint in this setting, we remain confident in the clinical efficacy of cabozantinib alone and in combination with another treatment in existing indications in difficult-to-treat tu

Verisign Reports Internet Has 349.9 Million Domain Name Registrations at the End of the Third Quarter of 20228.12.2022 21:57:00 CET | Press release

VeriSign, Inc. (NASDAQ: VRSN), a global provider of domain name registry services and internet infrastructure, today announced that the third quarter of 2022 closed with 349.9 million domain name registrations across all top-level domains, a decrease of 1.6 million domain name registrations, or 0.4%, compared to the second quarter of 2022.1,2 Domain name registrations have increased by 11.5 million, or 3.4%, year over year.1,2 The .com and .net TLDs had a combined total of 174.2 million domain name registrations in the domain name base3 at the end of the third quarter of 2022, a decrease of 0.2 million domain name registrations, or 0.1%, compared to the second quarter of 2022. The .com and .net TLDs had a combined increase of 2.1 million domain name registrations, or 1.2%, year over year. As of Sept. 30, 2022, the .com domain name base totaled 160.9 million domain name registrations, and the .net domain name base totaled 13.2 million domain name registrations. New .com and .net domain

Citi Global Wealth Investments Releases Outlook 2023: Roadmap to Recovery: Portfolios to Anticipate Opportunities8.12.2022 20:07:00 CET | Press release

Citi Global Wealth Investments (CGWI) today released its Wealth Outlook 2023 (Outlook) report, titled Roadmap to Recovery: Portfolios to Anticipate Opportunities. Published twice yearly, Outlook provides in-depth insights into the global economy and financial markets for the year ahead and beyond. The latest edition’s title reflects the investing journey that CGWI envisions and the steps that investors should consider diversifying their portfolios. In 2023, CGWI predicts the weakest annual global economic growth in forty years outside of the Global Financial Crisis and the COVID shutdowns. The year ahead is likely to see: A shallow US recession and worse in some other places such as the Eurozone A recovery in Chinese growth, by contrast, as pandemic restrictions are relaxed US inflation continuing to ease, ending 2023 at around 3.5% The US Federal Reserve to start cutting interest rates by the second half of the year A 10% drop in global earnings per share Just as 2022’s global market